Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
Checkpoint blockade therapy may sensitise non-Hodgkin lymphoma to subsequent therapy

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.12.18
Views: 894

Dr Nicole Carreau - NYU Langone Health, New York, USA

Dr Nicole Carreau speaks to ecancer at ASH 2018 on how checkpoint blockade therapy may sensitise non-Hodgkin lymphoma to subsequent therapy.

She describes how a retrospective analysis was conducted at 17 centres across the US and Canada where they evaluated the response to therapy after the checkpoint blockade.

Dr Carreau describes the statistical analysis conducted and the findings that indicated that checkpoint blockade therapy may sensitise patients to subsequent therapy. 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation